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Abstract 
Background and Aim: Urinary tract infections (UTIs) are one of the most common infectious diseases. Although UTI 
is mostly associated with several members of the family of Enterobacteriaceae, Escherichia coli (E. coli) is the most 
common pathogen among them. This study aims to determine the prevalence and resistance pattern of ESBL producing 
E. coli isolated from patients with urinary tract infection in Sari, Iran. 
Methods: From December-2016 to June-2017, a hospital-based cross-sectional work was accompanied, and a total 
of 200 urine samples were cultured on blood agar and MacConkey agar for the identification of etiologic agents. 
After detection and confirmation of E. coli isolates, susceptibility testing was assessed using the following 
antibiotics: cefotaxime, ceftazidime, imipenem, nalidixic acid, cefixime, amikacin, ofloxacin, ceftriaxone, cefepime, 
gentamicin, tobramycin, meropenem, piracetam, and ciprofloxacin with Kirby–Bauer disk-diffusion technique 
according to the CLSI guidelines. Double-disk synergy (DDS) methods were used for the detection of ESBL-
producing strains. 
Results: In the current study, 120 urinary isolates of E. coli were detected, which ESBL-producing phenotypes were 
detected in 55% (n=66) of the isolates. ESBL producing strains of E. coli showed the highest susceptibility to 
meropenem (100%) and ofloxacin (96%); and showed the highest rates of resistance to ceftazidime (91%), cefepime 
(87%), cefotaxime, and ceftriaxone (84%). 
Conclusion: Markedly high resistance to third-generation cephalosporins among E. coli strains was found in the current 
study. Considering the high prevalence of resistance to third-generation cephalosporins in infections caused by 
organisms producing ESBL, performing comprehensive tests before prescribing antibiotics is essential for the 
management of infections caused by these strains in community/hospital-acquired UTIs. Furthermore accompanying 
molecular-based works on ESBL variants will assistance to achieve better results. 
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Introduction 
Urinary tract infections (UTIs) are one of the most 
common infectious diseases after respiratory tract 
system infections; they infect a large number of 
people in developing countries each year (1). Due 
to anatomical structures and the hormonal settings 
of the urinary tract in females, women are 
remarkably more affected than men to develop a 
UTI. Approximately 50% of them will have a 
urinary tract infection during their lifetime (2, 3). 
UTI is common at all ages but aged people, 
children, and sexually active people may be at 
higher risk than others (4). UTIs can affect multiple 
organs including the urethra, bladder, ureter, and 
kidney (5). UTI is characterized by the existence of 
considerable numbers of pathogenic bacteria in the 
urinary system which needs convenient antibiotic 
intermediation to impede complications (6). 
Although UTI is mostly associated with several 
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members of the family of Enterobacteriaceae (7), 
Escherichia coli (E. coli) is the most common 
pathogen among them. Some pathotypes of E. coli 
are systematically associated with uropathogenicity 
and are designated as uropathogenic E. coli (UPEC) 
(6, 8, 9). The UPEC strains are responsible for most 
UTIs among ambulatory patients and also up to half 
of all hospital-acquired UTIs (10). As time goes on, 
E. coli is becoming resistant to the diversity of 
antibiotics that are vastly prescribed. This can cause 
a variety of complications in the management and 
therapeutic strategies of UTI. Various strategies are 
applied by bacteria to avoid the harmful effects of 
antibiotics (11,12). Extended-spectrum ß- 
lactamases (ESBLs) are enzymes generated by 
some gram-negative bacteria such as E. coli and can 
cause resistance to ß-lactam antibiotics. ESBLs 
catalyze the hydrolysis of the ß-lactam ring and 
subsequently make the antibiotics inactive (13). 
ESBL-producing bacteria are also ordinarily 
resistant to trimethoprim-sulfamethoxazole, 
quinolones, and aminoglycosides (14). Recent 
researches described that the mortality ratio 
amongst patients infected with ESBL-positive E. 
coli was higher than those infected with non-ESBL 
producing strains (15-17). Introducing the new 
generation of antibiotics such as broad-spectrum 
cephalosporins and aztreonam, as well as increasing 
their extended use in the treatment of bacterial 
infectious diseases, leads to the emergence of a new 
class of extended-spectrum beta-lactamase (18). 
The rise in ESBL-producer gram-negative strains 
ordinarily displays a multidrug resistance 
phenotype (MDR). Clinically, treatment of these 
multidrug-resistant bacteria still is a major concern 
(19). So, in this study, we aimed to investigate the 
frequency of ESBL production and the resistance 
pattern of ESBL-producer E. coli strains recovered 
from patients with urinary tract infections at Sari 
city hospitals.  
Methods 
Bacterial culture and identification 
In this descriptive, cross-sectional study, 200 urine 
samples were collected by midstream clean-catch 
during December-2016 and June-2017 from the 
educational hospitals of Sari. Specimens 
representing the UTIs among inpatients and 
outpatients attending teaching hospitals 
Mazandaran University of Medical Sciences were 
included in the work. The same samples recovered 
from one patient were excluded. A single type of 
bacteria with a colony count ≥of 105 CFU/mL for 
midstream urine was taken as a positive urine 
culture.  
To identify the gram-negative bacilli, the samples 
were cultured on blood and MacConkey agar plates 
(Merck, Darmstadt, Germany). The plates were 
incubated in aerobic conditions for 24 hours at 
37°C. Following the incubation, some bacteria were 
collected from colonies, and subsequently, gram 
staining and oxidase tests were performed. Oxidase-
negative samples were evaluated by deferential 
biochemical tests such as citrate, urea, indole, and 
movement test and they were identified precisely 
(20). 
ESBL screening 
The E. coli strains were analyzed for ESBL-
production by the combined disc method (CDT) in 
line with the clinical laboratory standard institute 
(CLSI) recommendation. For the CDT test, the 
standard concentration of bacterium was grass-
cultured on Muller- Hinton agar plate.  
As ceftazidime disk placed against ceftazidime 
clavulanic acid combined disk (10 μg, 30 μg) and 
cefotaxime disk placed against cefotaxime 
clavulanic acid combined disk (10 μg, 30 μg) (Mast 
Co., United Kingdom) with 15-millimeter spacing. 
Plates were incubated for 18-24 hours at 37°C. 
Zone of inhibition diameter around the clavulanic 
acid disk, as the ESBL enzyme inhibitor, was 
interpreted in the respect of that disk alone. 
Therefore, if the diameter of the zone of inhibition 
around clavulanic acid disks is larger than or equal 
to 5mm compared to the same disk alone, the strain 
can be taken as ESBL (20). 
Antimicrobial susceptibility testing 
Disc diffusion antibiotic sensitivity testing (Kirby-
Bauer antibiotic testing) was done for ESBL-
producer strains based on the CLSI guideline 2016. 
Antibiogram was performed using the Kirby-Bauer 
method on Muller–Hinton agar plate.  
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In this respect, one sterile swab immersed in 
0.5 McFarland suspension, and the strains were 
swabbed uniformly across a Muller–Hinton culture 
plate (Merck, Darmstadt, Germany).  
Antibiotic filter-paper disks were then placed on the 
surface of the agar by sterile forceps and plates 
have been incubated at 37° C for 18 hours. In this 
interval, the antibiotic diffused from the filter paper 
into the agar.  
The tested antibiotic disks were ceftazidime (30μg), 
ceftriaxone (30μg), cefotaxime (30μg), cefepime 
(30μg), nalidixic acid (30μg), ciprofloxacin (5μg), 
ofloxacin (5μg), imipenem (10μg), meropenem 
(10μg), and cotrimoxazole (10μg) (Mast Co., 
United Kingdom).  
After 18 hours, growth halo diameter was measured 
by ruler and the results were interpreted using CLSI 
instruction. In the condition that the antibiotic was 
effective against bacteria; no colonies grow around 
the disk which calls a zone of inhibition. The 
diameter of the zone of inhibition around each disk 
estimates the bacteria's sensitivity to that particular 
antibiotic disk. E. coli ATCC 25922 was used as a 
control strain. 
Data analysis 
The data were analyzed using SPSS version 16.0. 





Of total 200 urine samples were handled. Among 
which, 120 (60%) E. coli was isolated from 
samples. Among the E. coli positive samples, 
eighty-six (of 120, 71.66%) isolates were obtained 
from the inpatients, and thirty-four (of 120, 
28.33%) isolates were obtained from the 
outpatients. Out of all E. coli positive samples, 74 
patients (62%) were women and 46 of them (38%) 
were men. The age range of the patients infected 
with ESBL producing E. coli is shown in Figure 1. 
Their age ranged from 5 to 76 years old. The 
highest occurrence of infection with ESBL producer 
E. coli strains was observed in the first decade of 
life (32 patients; 27%); and the lowest incidence 
was detected in the 7th decade of life (6 patients; 
5%).Based on the results of CDT, among 120 tested 
isolates, 55% (n=66) of E. coli strains were 
confirmed as ESBL producers.  According to the 
results of antibiogram tests, meropenem (n= 66/66, 
100%) and ofloxacin (n=63/66, 96%) were found to 
be the most effective antibiotics against ESBL 
producing strains of E. coli. While, ceftazidime 
(n=60/66, 91%), cefepime (n=57/66, 87%), 
cefotaxime and ceftriaxone (n=56/66, 84%) showed 
the highest rates of resistance. Detailed results of 
antibiogram tests are presented in Figure 2. 
 
Figure 1. The age range of the patients infected with ESBL producing E. coli 
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Figure 2. Percentage of antimicrobial susceptibility in ESBL-producing E. coli strains. 
 
Discussion 
Although bacterial urinary tract infections are very 
common, it is not always possible to perform urine 
culture analysis and antibiotic sensitivity tests for 
the treatment, particularly in small therapy centers 
(21, 22). E. coli as one of the most important 
bacteria causing urinary tract infection is widely 
involved in several clinical infections (23, 24). In 
recent years, resistance towards antimicrobials has 
considerably increased and antibiotic-resistant 
infections are becoming an important clinical 
problem. Antibiotic resistance rates vary in 
different geographic places (25, 26). The incidence 
of ESBL-producing strains of E. coli isolated from 
urinary tract infections is diverse in different 
countries and from a hospital to another hospital; it 
depends on the infection control systems and 
therapeutic strategies (27). During the past few 
years, we have observed a significant increase in 
the resistant strains of E. coli which are resistant to 
the most first-line antibiotics, including third-
generation cephalosporin, aminoglycosides, and 
even fluoroquinolones (25, 26). This research 
displayed that 60% of samples were E. coli positive 
and our data was in coordination with Hamid-
Farahani et al (28), Madani et al (29), and Jha et al 
(30) studies; in which the E. coli infection was 
reported 54.1%, 60.3%, 45.4%, and 50%, 
respectively. In this study, 66% of isolated E. coli 
were ESBL-producing strain which was in 
accordance with Yazdi et al (27), Babypadmini et al 
(31), and Ejaz et al (32) findings that were 44.3%, 
41%, and 57.4%, respectively. Our results indicated 
that the most effective antibiotic against ESBL-
producing E. coli strains isolated from urinary tract 
infections was meropenem and ofloxacin. 
According to outcomes in the present study, we 
should use ceftazidime, cefepime, ceftriaxone, and 
cefotaxime less in initial treatment, due to high 
levels of resistance of ESBL-producing E. coli to 
these antibiotics. Rajabnia et al (33) demonstrated 
the resistance of ESBL-producing E. coli to 
ceftazidime 87.9% and cefepime 86.24% which 
were in accordance with our findings, 91%, and 
87%, respectively. In a study was done by Akya et 
al (34) the antibiotic resistance rate to cefotaxime 
and cotrimoxazole was 95.5% and 58.8%, 
respectively; which was almost in accordance with 
our results of 84% and 66%, respectively. Soltan 
Dalal et al (35) and Molaabaszadeh et al (36) 
among clinical isolates and urinary strains of E. coli 
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80.5% and 63.92%, respectively that were in 
agreement with our results of 66%. Mohajeri et al 
(37) reported the antibiotic resistance rate among 
ESBL positive E. coli strains, to cotrimoxazole, 
ofloxacin were 85.2%, 55.6%, and imipenem 0%; 
their results were different to our findings 66%, 0%, 
and 54% respectively; but their results about 
antibiotic resistance rate to ceftriaxone 90.7% and 
ciprofloxacin 55.5% were in agreement with our 
data (84% and 58% respectively). The results of 
this study and comparison with other studies 
indicated the antibiotic resistance in E. coli isolated 
from urinary tract infections. Therefore, applying 
new drugs such as meropenem that have shown 
very positive performance in different articles is 
recommended (38). Meropenem is a member of the 
carbapenems that is resistant to beta-lactamase 
enzymes (36). ESBL strains are a major threat to 
the cephalosporins administration. Therefore, 
estimating the prevalence of ESBL-producing E. 
coli, rapid identification of strains in the 
microbiology laboratories, and evaluating the 
pattern of antibiotic sensitivity is significantly and 
crucially important (27). 
Conclusion 
The occurrence of infections caused by ESBL-
producing organisms has increased noticeably in 
recent years. Our work showed an increase in the 
frequency of ESBL producing E. coli from 2007 to 
2017 for UTIs in Sari therapeutic centers. The 
resistance rates of antimicrobial agents, mainly 
third-generation broad-spectrum cephalosporins, 
showed a noteworthy increase in ESBL producing 
E. coli. Also, meropenem demonstrates good 
activity against ESBL-producing E. coli, in vitro. In 
conclusion, it is suggested, routine identification of 
ESBLs production of Enterobacteriaceae in 
hospitals' laboratory units along with antibiogram 
test and strong infection prevention strategies would 
be suitable to primary management of 
community/hospital-acquired UTIs. 
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